The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort

IntroductionThe study investigation examined the immune response to the Janssen Ad26.COV2.S COVID-19 vaccine within a Ugandan cohort, specifically targeting antibodies directed against spike (S) and nucleocapsid (N) proteins. We aimed to examine the durability and robustness of the induced antibody...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Jennifer Serwanga, Laban Kato, Gerald Kevin Oluka, Violet Ankunda, Jackson Sembera, Claire Baine, Isaac Kitabye, Angela Namuyanja, Solomon Opio, Joseph Ssebwana Katende, Peter Ejou, The COVID-19 Immunoprofiling Team, Pontiano Kaleebu
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Frontiers Media S.A. 2024-05-01
Serie:	Frontiers in Immunology
Ämnen:	Janssen Ad26.COV2.S vaccine SARS-CoV-2 immunity spike protein antibodies nucleocapsid protein antibodies Ugandan vaccine cohort single-dose vaccination
Länkar:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1384668/full
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!